Tyck till om SwePub Sök här!
onr:"swepub:oai:lup.lub.lu.se:d42480f5-a52a-4d4a-b48a-039d951d25f1"
Sökning: onr:"swepub:oai:lup.lub.lu.se:d42480f5-a52a-4d4a-b48a-039d951d25f1" > Characterization of...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Characterization of male breast cancer : Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
-
- Cardoso, F. (författare)
- Champalimaud Foundation,European Organisation for Research and Treatment of Cancer
-
- Bartlett, J. M.S. (författare)
- Ontario Institute for Cancer Research,University of Edinburgh,Erasmus University Medical Center,Dutch Breast Cancer Research Group (BOOG),Memorial Sloan-Kettering Cancer Center
-
- Slaets, L. (författare)
- European Organisation for Research and Treatment of Cancer
- visa fler...
- visa färre...
- (creator_code:org_t)
- Elsevier BV, 2018
- 2018
- Engelska.
- Ingår i: Annals of Oncology. - : Elsevier BV. - 1569-8041 .- 0923-7534. ; 29:2, s. 405-417
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases diagnosed during a 20-year period. Methods: Patients with follow-up and tumor samples, treated between 1990 and 2010, in 93 centers/9 countries. Samples were centrally analyzed in three laboratories (the United Kingdom, the Netherlands and the United States). Results: Of 1822 patients enrolled, 1483 were analyzed; 63.5% were diagnosed between 2001 and 2010, 57 (5.1%) had metastatic disease (M1). Median age at diagnosis: 68.4 years. Of 1054 M0 cases, 56.2% were node-negative (N0) and 48.5% had T1 tumors; 4% had breast conserving surgery (BCS), 18% sentinel lymph-node biopsy; half received adjuvant radiotherapy; 29.8% (neo)adjuvant chemotherapy and 76.8% adjuvant endocrine therapy (ET), mostly tamoxifen (88.4%). Per central pathology, for M0 tumors: 84.8% ductal invasive carcinomas, 51.5% grade 2; 99.3% estrogen receptor (ER)-positive; 81.9% progesterone receptor (PR)-positive; 96.9% androgen receptor (AR)-positive [ER, PR or AR Allred score ≥ 3]; 61.1% Ki67 expression low (<14% positive cells); using immunohistochemistry (IHC) surrogates, 41.9% were Luminal-A-like, 48.6% Luminal-B-like/HER-2-negative, 8.7% HER-2-positive, 0.3% triple negative. Median follow-up: 8.2 years (0.0-23.8) for all, 7.2 years (0.0-23.2), for M0, 2.6 years (0.0-12.7) for M1 patients. A significant improvement over time was observed in age-corrected BC mortality. BC-specific-mortality was higher for men younger than 50 years. Better overall (OS) and recurrence-free survival (RFS) were observed for highly ER+(P=0.001), highly PR+(P=0.002), highly AR+ disease (P=0.019). There was no association between OS/RFS and HER-2 status, Ki67, IHC subtypes nor grade. Conclusions: Male BC is usually ER, PR and AR-positive, Luminal B-like/HER2-negative. Of note, 56% patients had T1 tumors but only 4% had BCS. ER was highly positive in > 90% of cases but only 77% received adjuvant ET. ER, PR and AR were associated with OS and RFS, whereas grade, Ki67 and IHC surrogates were not. Significant improvement in survival over time was observed.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Clinical and biological characteristics
- Consortium
- Male breast cancer
- Retrospective analysis
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Cardoso, F.
- Bartlett, J. M.S ...
- Slaets, L.
- van Deurzen, C. ...
- van Leeuwen-Stok ...
- Porter, P.
- visa fler...
- Linderholm, B.
- Hedenfalk, I.
- Schröder, C.
- Martens, J.
- Bayani, J.
- van Asperen, C.
- Murray, M.
- Hudis, C.
- Middleton, L.
- Vermeij, J.
- Punie, K.
- Fraser, J.
- Nowaczyk, M.
- Rubio, I. T.
- Aebi, S.
- Kelly, C.
- Ruddy, K. J.
- Winer, E.
- Nilsson, C.
- Dal Lago, L.
- Korde, L.
- Benstead, K.
- Bogler, O.
- Goulioti, T.
- Peric, A.
- Litière, S.
- Aalders, K. C.
- Poncet, C.
- Tryfonidis, K.
- Giordano, S. H.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Annals of Oncolo ...
- Av lärosätet
- Lunds universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
